Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

Diabetic Foot Ulcers Clinical Trial

— PL-5  

Official title:

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Antimicrobial Peptide PL-5 Topical Spray in Patients With Mild Infections of Diabetic Foot Ulcers

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06189638
• Other study ID #: 280800-JSPL-PL-5-203
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 8, 2024
• Est. completion date: June 30, 2025

Study information

• Verified date: December 2023
• Source: Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
• Contact: Ming M Liu, MD, MS
• Phone: +86-15692176002
• Email: liu.ming[@]protelight.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the clinical efficacy and safety of Antimicrobial Peptide PL-5 Topical Spray in patients with mild infections of diabetic foot ulcers. Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (1‰), Antimicrobial Peptide PL-5 Topical Spray (2‰) and topical placebo (vehicle) spray. In this study, the cut-off date for final analysis is defined as the time when all subjects have completed the last visit or discontinued the study

Description:

This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the clinical efficacy and safety of Antimicrobial Peptide PL-5 Topical Spray in patients with mild infections of diabetic foot ulcers. Approximately 90 patients (30 per treatment group) will be randomized in this study. Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (1‰), Antimicrobial Peptide PL-5 Topical Spray (2‰) and placebo of Antimicrobial Peptide PL-5 Topical Spray (vehicle). In this study, the cut-off date for final analysis is defined as the time when all subjects have completed the last visit or discontinued the study. The duration of the whole study is planned for 24 months; the duration of each participant is about 4-5 weeks, including Screening period/Baseline (about 7 days), treatment period (about 14 days), Follow-up period (about 7-14 days). No interim analysis will be performed in this study. This study is a phase II study, and no statistical hypothesis is proposed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: June 30, 2025
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age between 18 to 65 years.

2. Non-hospitalized ambulatory subjects with Diabetes mellitus, Type I or II, according to the American Diabetes Association criteria.

3. HbA1c =12% at screening.

4. At baseline visit (after any required debridement), presence of Grade 2 diabetic foot infection [Grade 2 of the International Working Group on the Diabetic Foot (IWGDF) classification]

Infection present, as defined by the presence of at least 2 of the following items:

• Local swelling or induration

• Erythema >0.5 cm to =2 cm around the ulcer.

• Local tenderness or pain

• Local increased warmth

• Purulent discharge (thick, opaque to white, or sanguineous secretion)

Mild infection of an ulcer is defined as:

Presence of =2 manifestations of inflammation (purulence or erythema, tenderness, warmth, or induration), but any cellulitis/erythema extends =2cm around the ulcer, and infection is limited to the skin or superficial subcutaneous tissues; no other local complications or systemic illness.

5. Voluntary written consent, given before performance of any clinical investigation-related procedure not part of standard medical care, and with the understanding that consent may be withdrawn at any time without prejudice to future medical care.

6. Female subjects must meet at least one of the following additional criteria:

• Surgically sterile with bilateral tubal ligation or hysterectomy.

• Postmenopausal for at least one year.

• If of childbearing potential, practicing an acceptable method of birth control for the duration of the clinical investigation as judged by the Investigator, such as condoms, foams, jellies, diaphragm, intrauterine device or abstinence

Exclusion Criteria:

1. Another cause of the inflammatory response of the skin around the ulcer (such as a trauma, gout, acute Charcot neuro-arthropathy, fracture, thrombosis, or venous stasis).

2. Foot deformities, calluses, corns, ingrown nails, fungal infections, which will impact infection or wound healing based on Investigator's judgement.

3. Received any topical or systemic antimicrobial therapy within 7 days prior to study entry (Day 1).

4. Infected diabetic foot ulcer that is associated with local wound complications such as prosthetic materials or protruding surgical hardware.

5. > 1 infected foot ulcer.

6. Concurrent or expected to require systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.

7. Bone or joint involvement is suspected based on clinical examination or plain X-ray.

8. Arterial brachial index (ABI) <0.5 or ankle pressure <50 mmHg. If ABI is >1.3 (medial calcification is present), then only subjects meeting secondary testing requirements including either a toe pressure =30 mmHg, a transcutaneous pressure of oxygen =50 mmHg, or a skin perfusion pressure =40 mmHg are allowed. For subjects with ABI >1.3, only the initial secondary test after ABI should be used for this assessment. A documented ABI within 3 months prior to Screening is acceptable, as is the initially performed secondary testing method for subjects with ABI >1.3.

9. The subject is expected to be unable to care for the ulcer or return for all scheduled visits because of hospitalization, vacation, disability, etc. during the study period or cannot safely monitor the infection status at home.

10. Pregnant or lactating women.

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcers
• Foot Ulcer
• Infections
• Ulcer

Intervention

Drug:
• Antimicrobial Peptide PL-5 Topical Spray and Placebo
Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.

Locations

Country	Name	City	State
United States	Bay Area Foot Care	Castro Valley	California
United States	Crisp Regional Hospital	Cordele	Georgia
United States	South Florida Podiatry	Deerfield Beach	Florida
United States	Limb Preservation Platform, Inc.	Fresno	California
United States	Houston Foot and Ankle Care	Houston	Texas
United States	Scripps Clinical Research	La Jolla	California
United States	Central Arkansas VA Hospital	Little Rock	Arkansas
United States	Clemente Clinical Research	Los Angeles	California
United States	Felix Sigal - Foot and Ankle Clinic	Los Angeles	California
United States	Miami Dade Medical Research Institute, LLC	Miami	Florida
United States	Stanford Health Care (SHC) - Plastic and Reconstructive Surgery Clinic	Palo Alto	California
United States	Havana Research Institute	Pasadena	Florida
United States	Western University of Health Sciences	Pomona	California
United States	Doctor Research Network	South Miami	Florida
United States	Foot & Ankle Center of Illinois	Springfield	Illinois
United States	Essential Medical Research	Tulsa	Oklahoma
United States	Wake Forest Baptist Health - Wound Care and Hyperbaric Center	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.	Parexel

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wei Y, Wu J, Chen Y, Fan K, Yu X, Li X, Zhao Y, Li Y, Lv G, Song G, Rong X, Lin C, Wang H, Chen X, Zhang P, Han C, Zu H, Liu W, Zhang Y, Liu C, Su Y, Zhang B, Sun B, Wang L, Lai W, Liu J, Xia C, Ji G, Zhu F, Yu J, Ahemaiti A, Dong H, Chen M; PL-5 Investig — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical response	the Investigator will grade the clinical response as (1)"infection resolved or cured" (all signs and symptoms of infection resolved);(2)"infection improving"(most, but not all, signs and symptoms of infection improved or resolved)(3)"treatment failure" (=1 signs or symptoms of infection substantially worsening), (4)"unevaluable"(<3 days of study treatment or patient lost to follow-up), or (5)"recurrence"(a previously cured or improved infection showing worsening of signs or symptoms of infection)	At EOT (End-of-therapy: within 24 hours after the final dose)
Secondary	Microbiological response	Microbiological culture examination of wound tissue; Analysis of drug sensitivity test results; Analysis of MIC50, MIC90, geometric mean inhibitory concentration and range results of clinically isolated pathogenic bacteria. At baseline, day 1, and at all other study visits, Investigators will culture samples obtained from the wound at which culturable material and signs of infection are present. They will obtain specimens using tissue curettage with a sterile scalpel, place them into transport media, and ship them to the designated central laboratory for species identification and antibiotic susceptibility testing. For specific operations of bacteriological examination of wound tissue, please refer to the clinical microbiology operation manual. Result: 1)Resolved;2) Improved;3)Failure 4) Colonization 5) Superinfection.	Interim Clinical Evaluation (ICE): 7 days after the initiation of the study drug. End of Therapy (EOT): within 24 hours after the final dose. Post-therapy evaluation (PTE): 7-14 days after the final dose.
Secondary	Comprehensive Response	At EOT and PTE, the Investigator will grade the comprehensive response as (1)"cure"(patients are clinically cured, and the bacteria are eradicated or presumed eradicated.);(2)"failure" (patients are classified as clinical failure or/and microbiological responses are failure and superinfection) or (3)"indeterminate"(if both clinical and microbiological responses are indeterminate).	End of Therapy (EOT): within 24 hours after the final dose. Post-therapy evaluation (PTE):7-14 days after the final dose.
Secondary	Safety and tolerability	The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), and clinically significant changes in physical examination, vital signs, laboratory tests, and 12-lead electrocardiogram (ECG)	Interim Clinical Evaluation (ICE): 7 days after the initiation of the study drug. End of Therapy (EOT): within 24 hours after the final dose. Post-therapy evaluation (PTE): 7-14 days after the final dose
Secondary	Clinical response	At each visit after enrollment, the Investigator will grade the clinical response as (1)"infection resolved or cured" (all signs and symptoms of infection resolved);(2)"infection improving"(most, but not all, signs and symptoms of infection improved or resolved)(3)"treatment failure" (=1 signs or symptoms of infection substantially worsening), (4)"unevaluable"(<3 days of study treatment or patient lost to follow-up), or (5)"recurrence"(a previously cured or improved infection showing worsening of signs or symptoms of infection)	Interim Clinical Evaluation (ICE): 7 days after the initiation of the study drug. End of Therapy (EOT): within 24 hours after the final dose. Post-therapy evaluation (PTE): 7-14 days after the final dose.
Secondary	Wound infection Score and Total Wound Score	A "wound infection score" was semiquantitatively assessed by grading each of 7 parameters with a score of 0-3: (1) purulent drainage, (2) nonpurulent drainage, (3) erythema, (4) induration, (5) tenderness, (6) pain, and (7) local warmth.	At baseline, day 1, and at all other study visits, investigators will compile a "total wound score" that included ratings of signs and symptoms of infection, wound measurements (maximum length, width, and depth), and assessment of granulation tissue.

External Links

•   As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.